Long-term safety of selpercatinib for Rearranged during transfection ( RET) -activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time

Abstract excerpt

BACKGROUND: Selpercatinib is a selective RET inhibitor approved for treatment of RET-activated cancers. Adverse events (AEs) are manageable with dose modifications. This post hoc analysis characterized selpercatinib's clinical safety profile after long-term follow-up in the safety population of LIBRETTO-001. PATIENTS AND METHODS: LIBRETTO-001 is an ongoing phase I/II, single-arm, open-label trial (NCT03157128)....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Research and Treatments
• Share to Colorectal Cancer Treatments and Studies
• Share to Thyroid Cancer Diagnosis and Treatment